River Birch identifies, analyzes, and activates pharmaceutical investment opportunities through proprietary data infrastructure and deep sector expertise. We are the intelligence layer between capital and clinical innovation.
Our proprietary intelligence stack aggregates clinical trial data, regulatory filings, patent landscapes, and scientific literature to surface asymmetric opportunities in pharmaceutical markets.
Real-time monitoring of 14,000+ active clinical trials across Phase I–III with predictive modeling for trial success probability and readout timing.
FDA advisory committee tracking, PDUFA date calendars, and approval probability scores powered by NLP analysis of regulatory correspondence and precedent.
Comprehensive patent cliff analysis covering $800B+ in branded drug revenue, with generics market entry modeling and first-mover advantage scoring.
Multi-factor risk models spanning clinical, commercial, competitive, and macro dimensions — surfacing tail risks before they become consensus views.
Cross-border pricing dynamics, reimbursement landscape analysis, and health technology assessment (HTA) decision tracking across 40+ markets.
Proprietary deal-flow intelligence aggregating licensing activity, partnership structures, and strategic fit scoring across 200+ acquirer profiles.
We operate at the intersection of quantitative rigor and qualitative depth — where data science meets domain expertise.
Track record built on disciplined process, not market beta.
Concentrated pharma exposure with surgical allocation across therapeutic categories — maximizing domain edge.
We don't follow consensus. We build the analytical infrastructure that makes consensus irrelevant.
River Birch works with a select group of institutional partners, family offices, and strategic co-investors. Engagements are by introduction or application only.